scholarly journals The Impact of Human Papillomavirus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) on Nutritional Outcomes

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 514
Author(s):  
Jane Harrowfield ◽  
Elizabeth Isenring ◽  
Nicole Kiss ◽  
Erin Laing ◽  
Ruby Lipson-Smith ◽  
...  
Keyword(s):  
Weight Loss ◽  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Nutritional Status ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Nutritional Intervention ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Post Treatment ◽  
Nutritional Outcomes

Background: Patients undergoing (chemo) radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC) are at high risk of malnutrition during and after treatment. Malnutrition can lead to poor tolerance to treatment, treatment interruptions, poor quality of life (QOL) and potentially reduced survival rate. Human papillomavirus (HPV) is now known as the major cause of OPSCC. However, research regarding its effect on nutritional outcomes is limited. The aim of this study was to examine the relationship between HPV status and nutritional outcomes, including malnutrition and weight loss during and after patients’ (chemo) radiotherapy treatment for OPSCC. Methods: This was a longitudinal cohort study comparing the nutritional outcomes of HPV-positive and negative OPSCC patients undergoing (chemo) radiotherapy. The primary outcome was nutritional status as measured using the Patient Generated-Subjective Global Assessment (PG-SGA). Secondary outcomes included loss of weight, depression, QOL and adverse events. Results: Although HPV-positive were less likely to be malnourished according to PG-SGA at the beginning of treatment, we found that the difference between malnutrition rates in response to treatment was not significantly different over the course of radiotherapy and 3 months post treatment. HPV-positive participants had significantly higher odds of experiencing >10% weight loss at three months post-treatment than HPV-negative participants (OR = 49.68, 95% CI (2.7, 912.86) p ≤ 0.01). Conclusions: The nutritional status of HPV positive and negative patients were both negatively affected by treatment and require similarly intense nutritional intervention. In acute recovery, HPV positive patients may require more intense intervention. At 3- months post treatment, both groups still showed nutritional symptoms that require nutritional intervention so ongoing nutritional support is essential.

scholarly journals Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma

2019 ◽  
Vol 37 (29) ◽  
pp. 2661-2669 ◽  
Author(s):  
Bhishamjit S. Chera ◽  
Robert J. Amdur ◽  
Rebecca Green ◽  
Colette Shen ◽  
Gaorav Gupta ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Patient Reported Outcomes ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Post Treatment ◽  
Free Survival ◽  
Patient Reported

PURPOSE To report the results of a phase II clinical trial of de-intensified chemoradiotherapy for patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma. MATERIALS AND METHODS Major inclusion criteria were (1) having American Joint Committee on Cancer (AJCC) 7th edition T0-T3, N0-N2c, M0 (AJCC 8th edition T0-T3, N0-N2, M0), (2) being p16 positive, and (3) reporting minimal or remote smoking history. Treatment was limited to 60 Gy intensity-modulated radiotherapy with concurrent intravenous cisplatin 30 mg/m2 once per week. Patients with T0-T2 N0-1 (AJCC 7th edition) did not receive chemotherapy. All patients had a 10- to 12-week post-treatment positron emission tomography/computed tomography to assess for neck dissection. The primary end point was 2-year progression-free survival. Secondary end points included 2-year local-regional control, distant metastasis-free survival and overall survival, and patient-reported outcomes (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire and the patient-reported outcomes version of the Common Terminology Criteria for Adverse Events). RESULTS One hundred fourteen patients were enrolled (median follow-up of 31.8 months), with 81% having a minimum follow-up of 2 years. Eighty percent of patients had 10 or fewer tobacco pack-years. Two-year local-regional control, distant metastasis-free survival, progression-free survival, and overall survival were as follows: 95%, 91%, 86%, and 95%, respectively. Mean pre- and 2-year post-treatment European Organisation for Research and Treatment of Cancer quality of life scores were as follows: global, 79/84 (lower worse); swallowing, 8/9 (higher worse); and dry mouth, 14/45 (higher worse). Mean pre- and 2-year post-treatment patient-reported outcomes version of the Common Terminology Criteria for Adverse Events scores (0 to 4 scale, higher worse) were as follows: swallowing, 0.5/0.7, and dry mouth, 0.4/1.3. Thirty-four percent of patients required a feeding tube (median, 10.5 weeks; none permanent). There were no grade 3 or higher late adverse events. CONCLUSION Clinical outcomes with a de-intensified chemoradiotherapy regimen of 60 Gy intensity-modulated radiotherapy with concurrent low-dose cisplatin are favorable in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma. Neither neoadjuvant chemotherapy nor routine surgery is needed to obtain favorable results with de-escalation.

Transoral robotic surgery for oropharyngeal squamous cell carcinoma in the era of human papillomavirus

Head & Neck ◽  
2017 ◽  
Vol 40 (4) ◽  
pp. 710-721 ◽  
Author(s):  
Omar Mahmoud ◽  
Kim Sung ◽  
Francisco J. Civantos ◽  
Giovanna R. Thomas ◽  
Michael A. Samuels
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Robotic Surgery ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Transoral Robotic Surgery ◽  
Oropharyngeal Squamous Cell Carcinoma

Outcomes of relapsed human papillomavirus‐related oropharyngeal squamous cell carcinoma treated with curative intent

Head & Neck ◽  
2018 ◽  
Vol 41 (5) ◽  
pp. 1312-1319 ◽  
Author(s):  
Patrik Pipkorn ◽  
Parul Sinha ◽  
Dorina Kallogjeri ◽  
Douglas Adkins ◽  
Wade T. Thorstad ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Curative Intent

Current status of human papillomavirus positivity in oropharyngeal squamous cell carcinoma in Europe: a systematic review

2019 ◽  
Vol 139 (12) ◽  
pp. 1112-1116 ◽  
Author(s):  
Karoline Dyrberg Stjernstrøm ◽  
Jakob Schmidt Jensen ◽  
Kathrine Kronberg Jakobsen ◽  
Christian Grønhøj ◽  
Christian von Buchwald
Keyword(s):  
Systematic Review ◽  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Current Status

scholarly journals Raptor and rictor expression in patients with human papillomavirus-related oropharyngeal squamous cell carcinoma

2020 ◽  
Author(s):  
Shunsuke Kondo ◽  
Hitoshi Hirakawa ◽  
Taro Ikegami ◽  
Takayuki Uehara ◽  
Shinya Agena ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Cell Carcinoma ◽  
Cell Lines ◽  
Squamous Cell ◽  
Mtor Pathway ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
High Gene ◽  
Complex Expression

Abstract Background Despite reports of a link between human papillomavirus (HPV) infection and mechanistic target of rapamycin (mTOR) signaling activation, the role of the mTOR pathway, especially raptor and rictor, in HPV-related head and neck cancer is still unclear. The aim of the present study was to elucidate the role of the mTOR pathway in HPV-related oropharyngeal squamous cell carcinoma (OPSCC). Methods The present study involved two strategies. The first was to investigate the activity of mTOR and mTOR-related complexes in high-risk HPV-positive (UM-SCC47 and CaSki) and HPV-negative (SCC-4 and SAS) cancer cell lines. The second was to elucidate mTOR complex expression in 80 oropharyngeal cancer tissues and to examine the relationship between mTOR complex expression and survival in patients with OPSCC. Results The UM-SCC47 and CaSki cell lines showed high gene and protein expression of raptor. They also exhibited G1/S and G2/M phase cell cycle arrest following 24 h incubation with 6 μM temsirolimus, a rapamycin analog, and temsirolimus administration inhibited their growth. HPV-related OPSCC samples showed high gene expression of raptor and rictor compared with HPV-unrelated OPSCC. In addition, HPV-related OPSCC patients with high raptor and rictor expression tended to have a worse prognosis than those with low or medium expression. Conclusions These results suggest that raptor has an important role in HPV-related OPSCC and that temsirolimus is a potential therapeutic agent for patients with HPV-related OPSCC. This is the first report to reveal overexpression of raptor and rictor in HPV-related OPSCC.

Sign in / Sign up

Export Citation Format

Share Document